Marisa Wexler, MS,  senior science writer—

An experimental anti-inflammatory medication called DMX-700, being developed by Dimerix for chronic obstructive pulmonary disease (COPD), was found to substantially reduce lung injury in a mouse model of the disease. “DMX-700 has demonstrated some very encouraging pre-clinical data,” Nina Webster, PhD, CEO and managing director of Dimerix,…

Levels of a protein called LOXL1 are elevated in the lungs of people who smoke cigarettes, as well as in those with chronic obstructive pulmonary disease (COPD), a recent study reported. According to researchers, these findings highlight the importance of LOXL1 and similar proteins in disease processes associated with…

Levels of the protein fibrinogen in the blood can be used to assess inflammation and the risk of non-invasive ventilation failure during acute exacerbations in people with chronic obstructive pulmonary disease (COPD), according to a new study. Fibrinogen is an inflammation-associated protein that is known as a biomarker for…

A group of chronic obstructive pulmonary disease (COPD) patients in China has undergone surgery using Broncus Medical’s InterVapor system — the device’s first use in the country since its approval by Chinese regulators earlier this year — the company announced in a press release. These first surgeries using…

Using the gene-editing technology CRISPR, a team led by scientists at Boston University has shown that several genes previously associated with susceptibility to chronic obstructive pulmonary disease (COPD) affect the development of lung cells. The results specifically suggest that, in COPD, increased expression or activity of a gene called…

Scientists have developed a soft, wearable stethoscope that could make it easier to detect lung abnormalities that are indicative of chronic obstructive pulmonary disease (COPD). The new device was described in a study, “Fully portable continuous real-time auscultation with a soft wearable stethoscope designed for automated…

Enrollment is now complete in ENHANCE-1, a Phase 3 clinical trial testing Verona Pharma’s experimental inhalation therapy ensifentrine in more than 800 people with chronic obstructive pulmonary disease (COPD). The announcement comes less than five months after Verona completed enrollment in its other Phase 3 trial testing ensifentrine,…

A first-in-human clinical trial testing the safety and tolerability of EP395, EpiEndo Pharmaceuticals’ experimental treatment for chronic obstructive pulmonary disease (COPD), is now finished. EpiEndo is planning to launch a Phase 2a trial testing EP395 in people with COPD later this year. “The successful completion of this study…

Propeller Health has announced three new initiatives aiming to broaden the application of its technology, which connects a sensor to inhalers, allowing for detailed tracking of treatment in chronic obstructive pulmonary disease (COPD) and asthma. The goal, according to Propeller, is to implement “new solutions to bring [this]…

Respira Labs has raised $2.8 million to help develop a wearable device that uses sound to evaluate lung function in people with respiratory conditions, such as chronic obstructive pulmonary disease (COPD), asthma, and COVID-19. “We’re a U.S.-based startup excited to be making strides in a highly competitive space…